Archive 25/8/3

Here is the introduction of GSL2200, which is a world’s fastest glycan profiler adopting the evanescent wave fluorescence excitation method.

Even under the scanning condition that gives the highest sensitivity, the scanning time for one slide is only 10 seconds.
Because the scanning condition that produce the optimal image depends on the sample, scanning is usually performed using several different sets of scanning conditions.
For example, suppose you set the scanning conditions to exposure times of 1, 2, 4, 6, 8, and 10 seconds, even in this case, the total scanning time will be only 31 seconds.
In a case of a conventional laser scanning type scanners, the scanning time varies depending on the resolution setting, but the standard scanning time is around 5 to 10 minutes. If you set several scanning conditions under this type of scammer, the total scanning time can even exceed 30 minutes.
You can see how quickly the GSL2200 can do the job.

You may be concerned about the resolution, but there are absolutely no problems in practical use. The image above shows an example of an image obtained by scanning a LecChip.
The Limit of Detection (LOD) is also sufficiently high as high as 2 ng/mL, providing sufficient performance as a glycan profiler.

Here is a review paper written by a researcher in Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava, Slovakia about the role of glycans in human.
https://www.mdpi.com/1420-3049/30/13/2678

In this paper, therapeutic potentials targeting glycan-glycan-binding proteins (GBPs), such as selectins, galectins, and Siglecs, are summarized as follows.

1) Inhibition of GBP–glycan interactions, for example, Uproleselan (Glycomimetics)

2) Monoclonal antibodies targeting glycans, for example, Dinutuximab/Unituxin (National Cancer Institute) and Naxitamab/Danyelza (Memorial Sloan Kettering Cancer Center) to target ganglioside GD2

3) Carbohydrate-based vaccines against pathogens and cancer, for example, carbohydrate-based vaccine against the bacteria Haemophilus influenzae type b (Pentacel from Sanofi Pasteur, Hiberix, Merck and Co.), and as vaccines against cancer, Theratope (Biomira), GM2-KLH (Memorial Sloan Kettering Cancer Center), OPT-822 (OBI Pharma), and Racotumomab (Molecular Immunology Center in Havana) targeting sTn antigen, ganglioside GM2, glycolipid Globo H, and ganglioside GM3

4) Immune checkpoint inhibitor (ICI)

5) Altering the biosynthesis of carbohydrate determinants with carbohydrate processing inhibitors (CPIs)

Just for your information.